<DOC>
	<DOCNO>NCT00253968</DOCNO>
	<brief_summary>The purpose study assess efficacy safety eplivanserin population patient complain sleep maintenance insomnia . The patient suffer condition frequently wake night , sleep nonrestorative suffer significant distress impairment daily activity consecutive insomnia .</brief_summary>
	<brief_title>Efficacy Safety Eplivanserin Treatment Sleep Maintenance Insomnia</brief_title>
	<detailed_description>12 week patient ( double-blind period ) + 1 week run-in ( placebo ) , 2 week run-out ( placebo ) Total Duration observation : 15 week patient</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>SR 46349B</mesh_term>
	<criteria>Out patient Each patient must primary insomnia accordance DSMIVTRAxis I ( Diagnostic Statistical Manual Mental Disorders Fourth EditionText Revision ) criterion Based patient 's information , patient must complain least one hour wakefulness sleep onset least 3 night per week precede month Patient must report impact daytime functioning associate sleep maintenance insomnia measure question 3 Insomnia Severity Index screen visit randomization visit . Females lactate pregnant Woman childbearing potential positive serum beta human chorionic gonadotropin pregnancy test screen use acceptable form contraception Patients present acute chronic pain result insomnia Patients history epilepsy seizures Consumption xanthine contain beverage ( i.e . tea , coffee , cola ) comprise 5 glasses/day Evidence clinically significant , severe , unstable acute chronically progressive medical surgical disorder may affect patient safety BMI &gt; 32 Acute chronic pain result insomnia Patients current psychiatric disorder accord DSMIVTR criterion , mental retardation , dementia Clinically significant abnormal EKG ( QTc interval &gt; =500 msec ) Positive hepatitis B C Serious head injury stroke within 1 year Use OTC ( overthecounter ) medication valerian root , kava , melatonin , St. John 's Wort , alluna ; prescription sleep medication anxiolytic within 1 week 5 halflives Participation another trial within two month screen visit Use substance psychotropic effect property know affect sleep/wake Unable complete study questionnaire Night shift worker , individual nap 3 time per week precede month History : Primary hypersomnia Narcolepsy Breathingrelated sleep disorder ( sleep apnea ) Circadian rhythm sleep disorder Parasomnia ( somnambulism ) Dyssomnia ( periodic leg movement )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Primary Insomnia</keyword>
	<keyword>Sleeplessness</keyword>
	<keyword>Early Awakening</keyword>
	<keyword>Chronic Insomnia</keyword>
</DOC>